- Home
- UCL vs RLYB Comparison
UCL vs RLYB Comparison
Compare UCL & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- RLYB
- Stock Information
- Founded
- UCL 2014
- RLYB 2018
- Country
- UCL Hong Kong
- RLYB United States
- Employees
- UCL N/A
- RLYB N/A
- Industry
- UCL Telecommunications Equipment
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- RLYB Health Care
- Exchange
- UCL Nasdaq
- RLYB Nasdaq
- Market Cap
- UCL 48.7M
- RLYB 45.2M
- IPO Year
- UCL 2020
- RLYB 2021
- Fundamental
- Price
- UCL $2.13
- RLYB $0.95
- Analyst Decision
- UCL
- RLYB Buy
- Analyst Count
- UCL 0
- RLYB 6
- Target Price
- UCL N/A
- RLYB $8.10
- AVG Volume (30 Days)
- UCL 374.6K
- RLYB 105.7K
- Earning Date
- UCL 11-26-2024
- RLYB 11-07-2024
- Dividend Yield
- UCL N/A
- RLYB N/A
- EPS Growth
- UCL 169.91
- RLYB N/A
- EPS
- UCL 0.11
- RLYB N/A
- Revenue
- UCL $87,405,000.00
- RLYB $598,000.00
- Revenue This Year
- UCL $11.23
- RLYB N/A
- Revenue Next Year
- UCL $27.52
- RLYB N/A
- P/E Ratio
- UCL $18.65
- RLYB N/A
- Revenue Growth
- UCL 4.73
- RLYB N/A
- 52 Week Low
- UCL $0.97
- RLYB $0.93
- 52 Week High
- UCL $3.30
- RLYB $3.46
- Technical
- Relative Strength Index (RSI)
- UCL 62.21
- RLYB 37.53
- Support Level
- UCL $1.41
- RLYB $0.93
- Resistance Level
- UCL $3.30
- RLYB $1.24
- Average True Range (ATR)
- UCL 0.39
- RLYB 0.08
- MACD
- UCL 0.11
- RLYB -0.02
- Stochastic Oscillator
- UCL 45.33
- RLYB 6.45
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc provides mobile data connectivity and portable WiFi services. The business operates under uCloudlink 1.0, which focuses on cross-border travelers that need mobile data connectivity services across different countries. Under uCloudlink 2.0, provides mobile data connectivity services to local users across different MNOs in a single country. It generates revenue from the provision of data connectivity services, and the sales of terminals and sales of data related products.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.